A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients With High/High-Intermediate Risk Diffuse Large B-Cell Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 13 Apr 2016
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Pharmacogenomic; Therapeutic Use
- 08 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 14 Aug 2014 Planned End Date changed from 1 Jan 2016 to 1 Jul 2015 as reported by ClinicalTrials.gov .
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History